Publications in collaboration with researchers from GlaxoSmithKline (United Kingdom) (8)

2024

  1. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA)

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, Vol. 30, Núm. 2, pp. 223-230

  2. Risk factors for bloodstream infections due to carbapenem-resistant Enterobacterales: a nested case-control-control study

    Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 9, pp. 2132-2141

2023

  1. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

    eClinicalMedicine, Vol. 57

2021

  1. Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials

    BMC Health Services Research, Vol. 21, Núm. 1

2020

  1. Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks

    AIDS and Behavior, Vol. 24, Núm. 12, pp. 3533-3544

2019

  1. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

    The Lancet, Vol. 393, Núm. 10167, pp. 143-155

2018

  1. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

    The Lancet, Vol. 392, Núm. 10157, pp. 1519-1529

2013

  1. Dolutegravir plus Abacavir-Lamivudine for the treatment of HIV-1 infection

    New England Journal of Medicine, Vol. 369, Núm. 19, pp. 1807-1818